Reaction

Mucosal Dryness reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,973 reports · 41 co-occurring drugs

As of the last recalculation, Mucosal Dryness appears in 1,973 FAERS reports alongside 41 co-occurring drug terms. The strongest observed disproportionality signal is LETROZOLE (PRR 19.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Letrozole10819.519.5
Indapamide2816.716.7
Ado-Trastuzumab Emtansine1316.416.4
Letrozole Tablets6715.215.2
Pertuzumab3714.614.6
Linagliptin2212.912.9
Insulin Glargine-Yfgn2612.712.7
Exemestane2512.512.5
Isosorbide Mononitrate2412.312.4
Alpelisib1012.212.2
Fulvestrant3310.710.7
Diphenhydramine Hcl1110.510.5
Ribociclib289.59.5
Amitriptyline Hydrochloride159.19.1
Atropine Sulfate98.88.8
Nitrofurantoin138.48.4
Nitrofurantoin (Monohydrate/Macrocrystals)138.38.3
Itraconazole98.28.2
Lithium Carbonate138.18.1
Isotretinoin378.08.0
Derma Foam Excel Hand Sanitizer67.97.9
Ethanol67.97.9
Ramipril897.97.9
Fenofibrate257.57.5
Vemurafenib87.07.1
Trastuzumab426.66.6
Prochlorperazine166.16.1
Bupropion256.06.0
Peginterferon Alfa-2A305.95.9
Empagliflozin365.75.7
Granisetron55.05.0
Erlotinib44.44.4
Ixekizumab154.34.3
Paclitaxel (Aibumin-Bound)334.34.3
Erlotinib Hydrochloride54.24.2
Pemetrexed Disodium143.93.9
Dabigatran Etexilate273.73.7
Lapatinib53.43.4
Encorafenib33.23.2
Cabozantinib122.62.6
Osimertinib72.32.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.